|1.||Liu, W: 1 article (01/2016)|
|2.||Ng, Rrg: 1 article (01/2016)|
|3.||Chew, Sth: 1 article (01/2016)|
|4.||Caleb, M G: 1 article (01/2016)|
|5.||Goh, S G: 1 article (01/2016)|
|6.||Ti, L K: 1 article (01/2016)|
|7.||Ala-Kokko, Ti: 1 article (11/2011)|
|8.||Koskenkari, Jk: 1 article (11/2011)|
|9.||Mosorin, M: 1 article (11/2011)|
|10.||Savolainen, E-R: 1 article (11/2011)|
01/01/2016 - "The first CPB haematocrit was independently associated with AKI in the MCPB group (Relative Risk [RR]=0.484, 95% Confidence Interval [CI]=0.268-0.876, p=0.016); post-operative blood loss and inflammation were independently associated with AKI in the CCPB group (RR=1.005, 95%CI=1.003-1.007, p<0.001; RR=1.018, 95%CI=1.010-1.028, p<0.001). "
12/01/2005 - "Use of a MCPB affected inflammation and coagulation variables only marginally and did not lead to clinical relevant changes as assessed by blood loss, need for blood products, and intensive care unit and clinical stays. "
12/01/2005 - "We compared outcomes with conventional (CCPB) and miniaturized cardiopulmonary bypass (MCPB) after coronary artery bypass operations (CABG) with respect to inflammation and coagulation. "
11/01/2011 - "Polymorphonuclear leukocyte (PMN) elastase and von Willebrand factor release were statistically significantly reduced in the MCPB group, but there were no significant differences in other markers of inflammation, coagulation or endothelial activation. "
|1.||Leukocyte Elastase (Neutrophil Elastase)
|2.||von Willebrand Factor
|1.||Cardiopulmonary Bypass (Heart-Lung Bypass)
|2.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)